A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs BI 836826 (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 20 Jul 2017 Planned End Date changed from 1 Aug 2017 to 22 Jan 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 4 Dec 2017.
- 20 Jul 2017 Status changed from suspended to recruiting.